Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.
Journal article
Sarangarajan R. et al, (2020), Journal of racial and ethnic health disparities
Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
Journal article
Grozinsky-Glasberg S. et al, (2020), Endocrine-related cancer, 27, R345 - R355
Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells
Journal article
Lines KE. et al, (2020), Endocrine-Related Cancer, 27, 163 - 174
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function
Journal article
Fagan V. et al, (2019), Journal of Medicinal Chemistry
A genetics-led approach defines the drug target landscape of 30 immune-related traits
Journal article
Fang H. et al, (2019), Nature Genetics, 51, 1082 - 1091
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.
Journal article
Wu X. et al, (2019), Prostate
ANGIOTENSIN 2 TYPE 2 RECEPTOR BLOCKADE IS A NOVEL TARGET FOR MURINE OSTEOARTHRITIS PAIN
Conference paper
von Loga IS. et al, (2019), OSTEOARTHRITIS AND CARTILAGE, 27, S420 - S421
Organizational innovation for developing new medicines that target aging and age-related conditions.
Journal article
Ford GA. et al, (2019), J Gerontol A Biol Sci Med Sci
An Activity‐Based Probe Targeting Non‐Catalytic, Highly Conserved Amino Acid Residues within Bromodomains
Journal article
D'Ascenzio M. et al, (2019), Angewandte Chemie International Edition, 58, 1007 - 1012
Design, Synthesis and Characterization of Covalent KDM5 Inhibitors
Journal article
Vazquez‐Rodriguez S. et al, (2019), Angewandte Chemie International Edition, 58, 515 - 519
BROMODOMAIN INHIBITORS ARE POTENT EPIGENETIC REGULATORS OF CATABOLIC GENE EXPRESSION IN HUMAN OSTEOARTHRITIC CHONDROCYTES
Conference paper
de Andres MC. et al, (2018), OSTEOARTHRITIS AND CARTILAGE, 26, S154 - S154
Therapeutics discovery: From bench to first in-human trials.
Journal article
Al-Hujaily EM. et al, (2018), Biomed Rep, 8, 275 - 282
Open innovation in neuroscience research and drug discovery
Journal article
Hunter AJ. et al, (2018), Brain and Neuroscience Advances, 2, 239821281879927 - 239821281879927
The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery
Journal article
Bradley AR. et al, (2017), Essays in Biochemistry, 61, 495 - 503
Maximising value from a United Kingdom Biomedical Research Centre: study protocol.
Journal article
Greenhalgh T. et al, (2017), Health Res Policy Syst, 15
Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors
Journal article
Lines KE. et al, (2017), Oncogenesis, 6, e332 - e332
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.
Journal article
Tumber A. et al, (2017), Cell Chem Biol, 24, 371 - 380
Establishing a reliable framework for harnessing the creative power of the scientific crowd.
Journal article
Carter AJ. et al, (2017), PLoS Biol, 15
Assessing histone demethylase inhibitors in cells: lessons learned.
Journal article
Hatch SB. et al, (2017), Epigenetics Chromatin, 10